BACKGROUND OF THE INVENTION
Stem cells, which possess the unique ability to undergo self-renewal and differentiation into tissue-specific cells, give rise to all tissues in the body. Unlike embryonic stem cells which can differentiate into many different cell types, tissue specific stem cells can
BACKGROUND OF THE INVENTION
Stem cells, which possess the unique ability to undergo self-renewal and differentiation into tissue-specific cells, give rise to all tissues in the body. Unlike embryonic stem cells which can differentiate into many different cell types, tissue specific stem cells can
BACKGROUND OF INVENTION
The invention generally relates to phospholipids ether analogs and use thereof and specifically relates to use of phospholipid ether analogs and combinations thereof for diagnosis of metastasis, treatment, pharmacokinetic, dosimetry, and toxicity studies of various cancer
BACKGROUND OF INVENTION
The invention generally relates to phospholipids ether analogs and use thereof and specifically relates to use of phospholipid ether analogs and combinations thereof for diagnosis of metastasis, treatment, pharmacokinetic, dosimetry, and toxicity studies of various cancer
BACKGROUND OF INVENTION:
The invention generally relates to phospholipids ether analogs and use thereof and specifically relates to use of phospholipid ether analogs and combinations thereof for diagnosis of metastasis, treatment, pharmacokinetic, dosimetry, and toxicity studies of various cancer
FIELD OF INVENTION
This invention relates to compositions consisting of phospholipid encapsulated anthracycline anti-neoplastic agents. In another aspect it relates to the use of such compositions to deliver chemotherapeutic agents to tumors in a body.
BACKGROUND
Daunorubicin (also known as
BACKGROUND OF THE INVENTION
In 2012, 14.1 million people were diagnosed with cancer worldwide and 8.2 million died of cancer. In the United States, around 40% of all people will be diagnosed with cancer during their lifetime. Despite receiving the best treatment available, 44% of those Americans
BACKGROUND OF THE INVENTION
In 2012, 14.1 million people were diagnosed with cancer worldwide and 8.2 million died of cancer. In the United States, around 40% of all people will be diagnosed with cancer during their lifetime. Despite receiving the best treatment available, 44% of those Americans
BACKGROUND OF THE INVENTION
In 2012, 14.1 million people were diagnosed with cancer worldwide and 8.2 million died of cancer. In the United States, around 40% of all people will be diagnosed with cancer during their lifetime. Despite receiving the best treatment available, 44% of those Americans
This invention relates to a carcinostatic and immunostimulating agent containing a lysophospholipid and a phospholipid and a process for preparing the same as well as a method for treating cancerous diseases by administering said agent.
Lysophospholipids have very excellent carcinostatic and
This invention relates to phospholipids. More particularly, this invention relates to phospholipids of the formula ##STR3## wherein R.sup.1 and R.sup.2 are independently an aliphatic hydrocarbon residue containing 1 to 20 carbon atoms, with the numbers of the carbon atoms for both totalling 8 to 30,
The present invention concerns new substituted aminoalkanol phospholipids and methods for using the same.
The compounds of the invention correspond to the general formula I ##STR2## wherein X represents an oxygen or a sulphur atom and Y represents the radical --NR.sup.1 R.sup.2 or --OR.sup.3,
BACKGROUND OF THE INVENTION
This invention relates to radioiodinated compounds which are useful as radiopharmaceuticals and biological probes, and more specifically, to radioiodinated phospholipid ether analogues of the naturally-occurring ether alkyl lysophospholipid which are tumor-specific and
FIELD OF THE INVENTION
The present invention relates generally to the field of radiopharmaceuticals and biological probes, and more specifically to radiolabelled analogs of phospholipid ethers useful in cancer diagnosis and treatment.
BACKGROUND OF THE INVENTION
The early detection of cancer has
BACKGROUND OF THE INVENTION
Published European Patent Application 108 565 relates to compounds of the General Formula: ##STR3##
and their pharmaceutically acceptable salts, in which R.sup.1 is an aliphatic hydrocarbon radical having 8-30 carbon atoms and the radicals R.sup.2, R.sup.3 and R.sup.4 are
Најкомплетнија база лековитог биља подржана науком
Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи. * Све информације се заснивају на објављеним научним истраживањима